Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Publication | Open Access

DOI Full Paper Access

110

Citations

References

2016

Year

Peter Vuylsteke, Manon Huizing, Katarína Petráková, Rebecca Roylance, Robert Laing, Stephen Chan, F. Abell, Steven Gendreau, Isabelle Rooney, Doris Apt,

Annals of Oncology

Metastatic Breast CancerBreast OncologyPhase IiMedicinePharmacologyBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyEndocrine-related CancerPictilisib Pi3kinase Inhibitor